OBI Pharma’s OBI-999 Receives the US FDA’s Orphan Drug Designation for Pancreatic Cancer

 OBI Pharma’s OBI-999 Receives the US FDA’s Orphan Drug Designation for Pancreatic Cancer

OBI Pharma’s OBI-999 Receives the US FDA’s Orphan Drug Designation for Pancreatic Cancer

Shots:

  • OBI Pharma has initiated the enrollment of P-I/II study at the University of Texas M.D. Anderson Cancer Center to evaluate the therapy in patients with LA/m-solid tumors
  • The objective of the study is to assess the safety & preliminary efficacy profile of OBI-999 in patients with pancreatic, gastric, colorectal and esophageal cancers
  • OBI-999 is a first-in-class ADC targeting Globo H, a glycolipid antigen, utilizes validated IHC assay to select patients for P-II study. The ODD is granted to novel drugs and biologics which are intended for the safe and effective treatment, diagnosis or prevention of rare diseases affecting people less than 200,000 in the US

Click here to­ read full press release/ article | Ref: PRNewswire | Image: The Pharma Letter

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post